Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 Pharmacokinetics with Carbamazepine in Healthy Adults
NCT06893081Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mk-8527 in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from 0 to Infinity, Area Under the Concentration-Time Curve from 0 to Last Quantifiable Sample and 5 more. Started Apr 2025; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06893081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06893081.